Maximum quantity allowed is 999
Please select the quantity
CAS RN: 143664-11-3 | Product Number: E1371
Elacridar
×
![]()
×
Purity: >98.0%(HPLC)
Synonyms:
- N-[4-[2-(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-9,10-dihydro-5-methoxy-9-oxo-4-acridinecarboxamide
Product Documents:
| Size | Unit Price | Same Day | 2-3 Business Days | Other Lead Time |
Shipping Information
|
|---|---|---|---|---|---|
| 25MG |
$148.00
|
16 | 0 | Contact Us | |
| 100MG |
$446.00
|
35 | 1 | Contact Us |
* Please contact our distributors or
TCI
to order our products. The above prices do not include freight cost, customs, and other charges to the destination.
* The storage conditions are subject to change without notice.
| Product Number | E1371 |
| Purity / Analysis Method | >98.0%(HPLC) |
| Molecular Formula / Molecular Weight | C__3__4H__3__3N__3O__5 = 563.65 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Frozen (<0°C) |
| Condition to Avoid | Heat Sensitive |
| Packaging and Container | 100MG-Glass Bottle with Plastic Insert (View image), 25MG-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 143664-11-3 |
| Reaxys Registry Number | 7324887 |
| PubChem Substance ID | 468591739 |
| MDL Number | MFCD00912604 |
Specifications
| Appearance | White to Yellow to Green powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
Properties (reference)
| Melting Point | 210 °C |
GHS
| Hazard Statements | H413 : May cause long lasting harmful effects to aquatic life. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P273 : Avoid release to the environment. |
Related Laws:
| RTECS# | AR7621300 |
Transport Information:
| H.S.code* | 2933.99-000 |
Application
Elacridar: A Potent Dual Inhibitor of Breast Cancer Resistance Protein (BCRP) and P-Glycoprotein (P-gp)
Elacridar (GF120918) is a potent dual inhibitor of breast cancer resistance protein (BCRP) and P-glycoprotein (P-gp). BCPR is a member of ATP-binding cassette family of drug transporters. P-gp, known as multidrug resistance protein 1 (MDR1), is an ATP-binding protein of the cell membrane that pumps many foreign substances out of cells. Therefore, it is believed that elacridar increases oral bioavailability of topotecan, a topoisomerase inhibitor. (The product is for research purpose only.)
References
- In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative
- Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan
- Therapeutic Potential and Utility of Elacridar with Respect to P-glycoprotein Inhibition: An Insight from the Published In Vitro, Preclinical and Clinical Studies (a review)
- Bioanalysis and preliminary pharmacokinetics of the acridonecarboxamide derivative GF120918 in plasma of mice and humans by ion-pairing reversed-phase high-performance liquid chromatography with fluorescence detection
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.